Intracellular pH gradient (pHi gradient)

The intracellular pH gradient refers to the spatial variation in hydrogen ion concentration within cells and across different cellular compartments. Physiologically, normal intracellular pH ranges from 7.0 to 7.4 in most mammalian cells, though this varies by tissue type. Within cells, pH gradients exist both spatially during processes like cell migration (with more alkaline pH at the leading edge) and across organelles (ranging from pH 4.5 in lysosomes to pH 8.0 in mitochondrial matrix). These gradients are maintained by membrane transporters including the sodium-hydrogen exchanger (NHE1), sodium-bicarbonate cotransporter, chloride-bicarbonate exchanger, and vacuolar-ATPase, along with intracellular buffering systems involving proteins and phosphates. Intracellular pH gradients play critical roles in cell migration, proliferation, differentiation, stem cell lineage specification, and metabolic regulation. In cancer cells, a reverse pH gradient is a hallmark feature, characterized by intracellular alkalization that maximizes proliferation and adaptation to hypoxia. The gradient is essential for intestinal stem cell differentiation along the crypt column and regulates various cell fate decisions. Disruption of pH gradients through NHE1 inhibition has shown therapeutic potential, particularly in cancer treatment where it can block differentiation, compromise tumor growth, and sensitize aggressive phenotypes to therapy.

Other names

Intracellular pH dynamicspHi gradientCytoplasmic pH gradientIntracellular proton gradient

Drugs interact with the intracellular pH gradient primarily through: Inhibition of sodium-hydrogen exchanger 1 (NHE1) to disrupt pH gradients; Modulation of vacuolar-ATPase activity; Targeting pH-dependent metabolic enzymes (GAPDH, GPI); Alteration of acid extrusion systems; Modification of acid loading systems.